Calliditas Therapeutics AB (publ)
NASDAQ: CALT0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Global Select
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Renee Aguiar-Lucander
- Employees
- 222
- Headquarters
- Stockholm, Sweden
- IPO year
- 2020
- Market cap
- $2.1B
- Website
- https://www.calliditas.se
Loading CALT…
Loading profile data…Frequently asked questions about CALT
What does Calliditas Therapeutics AB (publ) (CALT) do?
Calliditas Therapeutics AB (publ) operates as a clinical-stage biopharmaceutical entity, committed to identifying, advancing, and commercializing therapeutic products. Its primary focus lies in developing treatments for rare (orphan) conditions, with a particular emphasis on disorders impacting the renal and hepatic systems. The company markets...
Where does CALT trade?
Calliditas Therapeutics AB (publ) (CALT) trades on the NASDAQ Global Select.
What sector is CALT in?
Calliditas Therapeutics AB (publ) (CALT) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Calliditas Therapeutics AB (publ)?
Renee Aguiar-Lucander is the chief executive officer of Calliditas Therapeutics AB (publ) (CALT).
Where is Calliditas Therapeutics AB (publ) headquartered?
Calliditas Therapeutics AB (publ) is headquartered in Sweden.
Does CALT pay a dividend?
Calliditas Therapeutics AB (publ) (CALT) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did CALT go public?
Calliditas Therapeutics AB (publ) (CALT) completed its initial public offering in 2020.
Is CALT an ADR?
Yes — CALT is an American Depositary Receipt; its underlying shares trade on a non-US exchange. Calliditas Therapeutics AB (publ) reporting and dividends follow the underlying issuer.